Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like GSK Gets a Partial Thumbs Up for Anemia Drug, Ends Plans for RA Drug October 27, 2022 Protalix and Chiesi Report Positive Results From Fabry Disease Trial March 21, 2022 Roche’s Ocrevus Demonstrates Hints of Disease Modification, Cognitive Boost April 4, 2022